Stereotactic radiosurgery for cavernous sinus hemangiomas

We performed this retrospective study to analyze the outcome of patients with cavernous sinus hemangioma (CSH) after stereotactic radiosurgery (SRS). We analyzed 19 patients with CSHs who were treated with SRS between 1998 and 2011. The median age of the patients was 50 years (range, 35–73 years), and 16 (84.2 %) of the patients were female. SRS was performed as a primary treatment for 18 patients and to treat a residual lesion after surgical resection in one patient. Nine (47.4 %) patients had cranial neuropathies in 14 cranial nerves before SRS, whereas five (26.3 %) patients were initially asymptomatic. The mean volume of the CSHs was 6.1 ± 7.2 cm3 (range, 0.3–32.3 cm3), and the median marginal dose at the 50 % isodose line was 14.5 Gy (range, 11.5–16.0 Gy). The mean follow-up period was 37 months (range, 12–85 months). At the last follow-up, the lesion volume had decreased in all patients. The average tumor volume had decreased to 26 % (range, 0–70 %) of the initial volume at the last follow-up MRI. The first follow-up MRI, performed 6.1 ± 1.0 months after the SRS, showed that the tumor volume had decreased to 41 % (range, 0–88 %) of the initial volume. All 14 of the cranial neuropathies observed before SRS had improved, with complete remission in 12 (85.7 %) cranial nerves and partial remission in two (14.3 %). There were no radiation-induced neuropathies or complications during the follow-up period. SRS appears to be an effective and safe treatment modality for the management of CSHs.